-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, OlSu/3Yv8mJp06BuyW4Nmtt5QNoS+46vCL4NX5TeDvoipXE3t+o8JrokcoVCV1VB 2IVfZWeecisWCB9ej52E+g== 0000950133-04-004530.txt : 20041208 0000950133-04-004530.hdr.sgml : 20041208 20041208094620 ACCESSION NUMBER: 0000950133-04-004530 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20041208 DATE AS OF CHANGE: 20041208 GROUP MEMBERS: BIOTECH TARGET N.V. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: POZEN INC /NC CENTRAL INDEX KEY: 0001059790 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 621657552 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-59871 FILM NUMBER: 041189785 BUSINESS ADDRESS: STREET 1: 6330 QUADRANGLE DR STREET 2: SUITE 240 CITY: CHAPEL HILL STATE: NC ZIP: 27514 BUSINESS PHONE: 9194900012 MAIL ADDRESS: STREET 1: 6330 QUADRANGLE DR STREET 2: SUITE 240 CITY: CHAPEL HILL STATE: NC ZIP: 27514 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BB BIOTECH AG CENTRAL INDEX KEY: 0000924223 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: VODERGASSE 3 STREET 2: SWITZERLAND CITY: SCHAFFHAUSEN STATE: V8 ZIP: CH-8300 BUSINESS PHONE: 411724 59 59 MAIL ADDRESS: STREET 1: VODERGASSE 3 STREET 2: SWITZERLAND CITY: SCHAFFHAUSEN STATE: V8 ZIP: CH-8300 SC 13G/A 1 w69432sc13gza.htm AMENDMENT NO. 1 sc13gza
 

United States
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

Pozen, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

73941U102

(CUSIP Number)

December 2, 2004

(Date of Event Which Requires Filing This Statement)

     Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

         
    o Rule 13d-1(b)
    x Rule 13d-1(c)
    o Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed”
for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise
subject to the liabilities of that section of the Act but shall be subject to all other provisions of the
Act (however, see the Notes).

 

 

     
  CUSIP No.                        73941U102                       
             
1.
   Names of Reporting Persons Biotech Target N.V.      
 
     
 
    I.R.S. Identification Nos. of above persons (entities only): N/A      
 
     
2.
   Check the Appropriate Box if a Member of a Group (See Instructions)  
 
   (a)    x  
 
   (b)    o  
 
3.
   SEC Use Only        
 
     
 
4.
   Citizenship or Place of Organization Netherlands Antilles      
 
     

  Number of Shares  
5.
   Sole Voting Power 0
  Beneficially Owned by Each  
  Reporting Person with:  
 
   
6.
   Shared Voting Power 1,390,700
   
 
   
7.
   Sole Dispositive Power 0
   
 
   
8.
   Shared Dispositive Power 1,390,700
   

9.
   Aggregate Amount Beneficially Owned
by Each Reporting Person		 1,390,700  
   
 
 
10.
   Check if the Aggregate Amount in Row (9) Excludes Certain Shares o  
 
11.
   Percent of Class Represented by amount in Row (9) 4.8%  
   
 
 
12.
   Type of Reporting Person (See Instructions) CO  
   
 

2

 

     
  CUSIP No.                        73941U102                       
             
1.
   Names of Reporting Persons BB Biotech AG      
 
     
 
    I.R.S. Identification Nos. of above persons (entities only): N/A      
 
     
2.
   Check the Appropriate Box if a Member of a Group (See Instructions)  
 
   (a)    x  
 
   (b)    o  
 
3.
   SEC Use Only        
 
     
 
4.
   Citizenship or Place of Organization Switzerland      
 
     

  Number of Shares  
5.
   Sole Voting Power 0
  Beneficially Owned by Each  
  Reporting Person with:  
 
   
6.
   Shared Voting Power 1,390,700
   
 
   
7.
   Sole Dispositive Power 0
   
 
   
8.
   Shared Dispositive Power 1,390,700
   

9.
   Aggregate Amount Beneficially Owned
by Each Reporting Person		 1,390,700  
   
 
 
10.
   Check if the Aggregate Amount in Row (9) Excludes Certain Shares o  
 
11.
   Percent of Class Represented by amount in Row (9) 4.8%  
   
 
 
12.
   Type of Reporting Person (See Instructions) CO, HC  
   
 

3

 

Item 4. Ownership

     Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

                   
  (a)   Amount beneficially owned:     1,390,700    
         
 
  (b)   Percent of class:     4.8%  
         
 
    (c)   Number of shares as to which the person has:  
                 
  (i)   Sole power to vote or to direct the vote     0  
         
  (ii)   Shared power to vote or to direct the vote     1,390,700  
         
  (iii)   Sole power to dispose or to direct the disposition of     0  
         
  (iv)   Shared power to dispose or to direct the disposition of     1,390,700  
         

Item 5. Ownership of Five Percent or Less of a Class

     If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

Item 10. Certification

     By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

4

 

SIGNATURES

     After reasonable inquiry and the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BB Biotech AG

             
Date:
December 6, 2004
  By:  
/s/ Adrian Brüngger
Signatory Authority
           
        Name:  
Adrian Brüngger
           
        Title:  
Signatory Authority
           
           
Date:
December 6, 2004
  By:  
/s/ Roland Maier
Signatory Authority
           
        Name:  
Roland Maier
           
        Title:  
Signatory Authority
           
           
Biotech Target N.V.
           
           
Date:
December 6, 2004
  By:  
/s/ Adrian Brüngger
Signatory Authority
           
        Name:  
Adrian Brüngger
           
        Title:  
Signatory Authority
           
           
Date:
December 6, 2004
  By:  
/s/ Roland Maier
Signatory Authority
           
        Name:  
Roland Maier
           
        Title:  
Signatory Authority

5

 

Exhibit Index

    Exhibit 1: Agreement by and between BB Biotech AG and Biotech Target N.V. with respect to the filing of this disclosure statement.1

 

 

 

 

 

1   Previously filed.

 

-----END PRIVACY-ENHANCED MESSAGE-----